ADVFN Logo
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Monopar Therapeutics Inc

Monopar Therapeutics Inc (MNPR)

4.50
0.56
(14.21%)
Closed September 19 4:00PM
4.35
-0.15
(-3.33%)
After Hours: 7:56PM

Professional-Grade Tools, for Individual Investors.

Key stats and details

Current Price
4.35
Bid
4.25
Ask
4.45
Volume
247,820
3.90 Day's Range 4.61
1.3695 52 Week Range 8.65
Market Cap
Previous Close
3.94
Open
3.90
Last Trade
1
@
4.4
Last Trade Time
Financial Volume
$ 1,080,281
VWAP
4.3591
Average Volume (3m)
843,346
Shares Outstanding
3,520,365
Dividend Yield
-
PE Ratio
-1.88
Earnings Per Share (EPS)
-2.39
Revenue
-
Net Profit
-8.4M

About Monopar Therapeutics Inc

Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of?Validive?for the prevention of chemoradiotherapy-induced severe oral mu... Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of?Validive?for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicin?for the treatment?of advanced soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for advanced cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Headquarters
Wilmington, Delaware, USA
Founded
-
Monopar Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker MNPR. The last closing price for Monopar Therapeutics was $3.94. Over the last year, Monopar Therapeutics shares have traded in a share price range of $ 1.3695 to $ 8.65.

Monopar Therapeutics currently has 3,520,365 shares outstanding. The market capitalization of Monopar Therapeutics is $13.87 million. Monopar Therapeutics has a price to earnings ratio (PE ratio) of -1.88.

MNPR Latest News

Monopar Announces Positive Early Human Clinical Data Validating the Tumor Targeting Ability of MNPR-101-Zr

WILMETTE, Ill., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage radiopharma company focused on developing innovative treatments for cancer patients...

Monopar to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

WILMETTE, Ill., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer...

Monopar Regains Compliance with Nasdaq Minimum Bid Price Rule

WILMETTE, Ill., Aug. 27, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage radiopharma company focused on developing innovative treatments for cancer patients...

Monopar Receives Clearance to Proceed with Phase 1 Therapeutic Trial of Novel Radiopharmaceutical in Advanced Cancers

WILMETTE, Ill., Aug. 21, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage radiopharma company focused on developing innovative treatments for cancer patients...

Monopar Announces Initial Data for First Patient Dosed in Radiopharma Phase 1 Clinical Trial of MNPR-101-Zr

WILMETTE, Ill., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage radiopharma company focused on developing innovative treatments for cancer patients...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.8-15.53398058255.155.44063.1785065503.95143056CS
41.7164.77272727272.645.44062.2522583513.93914016CS
120.67518.36734693883.6755.44061.7198433463.81627327CS
260.512.9870129873.855.44061.7194679483.80154638CS
521.35845.38770053482.9928.651.369518429184.53647793CS
156-20.8-82.70377733625.1528.71.36956681474.73156713CS
260-116.35-96.396023198120.72401.36954551347.72849555CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
GSIWGarden Stage Ltd
$ 8.17
(259.91%)
70.64M
ZEOZeo Energy Corporation
$ 2.5995
(128.03%)
59.98M
TBIOTelesis Bio Inc
$ 2.9201
(114.71%)
53.74M
NCINeo Concept International Group Holdings Ltd
$ 0.84
(71.43%)
12.68M
VEROVenus Concept Inc
$ 0.8475
(68.66%)
20.56M
HAOHaoxi Health Technology Ltd
$ 0.83
(-72.33%)
8.28M
PGNYProgyny Inc
$ 16.465
(-32.63%)
19.16M
NUZENuZee Inc
$ 0.6998
(-32.06%)
14.06M
RGFReal Good Food Company Inc
$ 0.308
(-28.37%)
363.05k
ALGSAligos Therapeutics Inc
$ 10.18
(-28.11%)
875.5k
NVDANVIDIA Corporation
$ 117.87
(3.97%)
293.54M
SQQQProShares UltraPro Short QQQ
$ 7.76
(-7.62%)
222.56M
HOLOMicroCloud Hologram Inc
$ 0.2328
(15.08%)
120.19M
MAXNMaxeon Solar Technologies Ltd
$ 0.1034
(13.75%)
105.03M
TSLATesla Inc
$ 243.92
(7.36%)
102.7M

MNPR Discussion

View Posts
Dell_Griffith Dell_Griffith 7 days ago
You’re welcome. May take some time, but these are certainly not small-time players.

Regardless, if they’ve got a better way to treat people with illnesses, that’s a win-win.
👍️0
subslover subslover 1 week ago
Hi Dell. That is some great DD you did and I thank you for letting me know. I have never even bought this stock, I just reported the news but now I will be looking for dips to possibly take at least a small starters position. Hope you are doing well and please stay in touch :)😍
👍️ 1
Dell_Griffith Dell_Griffith 1 week ago
Good info. Just checked this out today. Pretty damn impressive group of execs - CEO and COO went to Stanford. COO has a long history, including selling off companies he was CEO of to major players.

Bought a little high and was looking to flip, but I think I’m going to hold this one.
👍️0
subslover subslover 1 week ago
Monopar Announces Positive Early Human Clinical Data Validating the Tumor Targeting Ability of MNPR-101-Zr
WILMETTE, Ill., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage radiopharma company focused on developing innovative treatments for cancer patients, today announced positive early data from its ongoing open-label MNPR-101-Zr Phase 1 imaging and dosimetry clinical trial confirming MNPR-101-Zr’s tumor targeting ability in humans.

MNPR-101 is Monopar’s proprietary first-in-class humanized monoclonal antibody that targets cancers expressing the urokinase plasminogen activator receptor (uPAR). These include a majority of all triple-negative breast, colorectal, bladder, ovarian, gastric, and pancreatic cancers.

A total-body positron emission tomography (PET) image was taken at 168 hours (7 days) post administration of MNPR-101-Zr (a zirconium-89 imaging radioisotope conjugated to MNPR-101) of the first cancer patient in the trial with one of the known high uPAR-expressing cancer types. The results, seen in Figure 1, demonstrate the specificity, durability, and uptake of MNPR-101-Zr in the metastatic tumors relative to normal tissue. The regions of higher uptake also align with the locations of the previously observed metastatic tumors on conventional FDG PET imaging.

https://ml.globenewswire.com/Resource/Download/cda29080-7e74-46b0-8b93-5925a209f2ab/2024-9-11-pr-figure-1-jpeg.jpg

“This is exactly what we had hoped to see – highly preferential uptake in the tumor,” said Andrew Cittadine, Monopar’s Chief Operating Officer.

MNPR-101-Zr was evaluated against FDG, the gold standard for detecting metastatic tumors. Figure 2 shows FDG uptake in its highest-uptake tumor compared to MNPR-101-Zr uptake in the same tumor imaged on the same Siemens Biograph Vision Quadra™ PET/CT scanner.

https://ml.globenewswire.com/Resource/Download/cb0b4c63-91dc-46e1-a3c5-862ccc4251d8/2024-9-11-pr-figure-2-jpeg.jpg

“At the Melbourne Theranostic Innovation Centre, we utilize one of the world's most sensitive PET/CT scanners. Using the same scanner for FDG and MNPR-101-Zr, the results show MNPR-101-Zr achieved uptake at sites of known disease with retention out to late points, which is promising for future therapeutic translation,” said Professor Rodney Hicks, MBBS(Hons), MD, FRACP, FICIS, FAAHMS, lead investigator on the MNPR-101-Zr Phase 1 imaging and dosimetry clinical trial.

Monopar recently received clearance in Australia to initiate an MNPR-101-Lu Phase 1 therapeutic clinical trial [link] which is currently scheduled to launch in the fourth quarter of this calendar year.

“We are looking forward to sharing additional data at the upcoming European Association of Nuclear Medicine 2024 Annual Congress to be held in Hamburg, Germany on October 19-23, 2024, where our abstract has been accepted as a 'Top-Rated Oral Presentation' within the Scientific Program,” said Chandler Robinson, MD, Monopar’s Chief Executive Officer.

Further information about the ongoing MNPR-101-Zr Phase 1 imaging and dosimetry clinical trial is available at www.ClinicalTrials.gov under study identifier NCT06337084.

About Monopar Therapeutics Inc.

Monopar?Therapeutics is a clinical-stage radiopharmaceutical company focused on developing innovative treatments for cancer patients, including Phase 1-stage MNPR-101-Zr for imaging advanced cancers, Phase 1-stage MNPR-101-Lu and late preclinical-stage MNPR-101-Ac225 for the treatment of advanced cancers, as well as early development stage programs against solid cancers. For more information, visit: www.monopartx.com.

Forward-Looking Statements

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Examples of these forward-looking statements include: the results show MNPR-101-Zr achieved uptake at sites of known disease with retention out to late points, which is promising for future therapeutic translation; and that an MNPR-101-Lu Phase 1 therapeutic clinic
👍️ 1
tw0122 tw0122 1 week ago
$5.30 and 6.75 on high side and then $2.95- $4 is where most of the action will
Play out
👍️0
Awl416 Awl416 1 week ago
Monopar Announces Positive Early Human Clinical Data Validating the Tumor Targeting Ability of MNPR-101-Zr
👍️0
glenn1919 glenn1919 4 weeks ago
MNPR.............................https://stockcharts.com/h-sc/ui?s=MNPR&p=W&b=5&g=0&id=p86431144783
👍️0
glenn1919 glenn1919 4 weeks ago
MNPR.........................................https://stockcharts.com/h-sc/ui?s=MNPR&p=W&b=5&g=0&id=p86431144783
👍️0
Awl416 Awl416 4 weeks ago

On August 21, 2024, Monopar Therapeutics Inc. (Monopar) issued a press release announcing that Monopar has received Human Research Ethics Committee (HREC) clearance in Australia to commence a Phase 1 therapeutic trial of its novel radiopharmaceutical MNPR-101-Lu.
👍️0
PonkenPlonken PonkenPlonken 3 months ago
who killed the radiostar?
looking very great down here
👍️0
Laster Laster 3 months ago
Stock up 50% recently. Quietly moving higher.
They will report some data soon. Running in anticipation?
I like this stock a lot.
I think it has more to go.
JMO
👍️0
TIMGZ TIMGZ 7 months ago
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173913331
👍️0
glenn1919 glenn1919 7 months ago
MNPR................................................https://stockcharts.com/h-sc/ui?s=MNPR&p=W&b=5&g=0&id=p86431144783
👍️0
Invest-in-America Invest-in-America 7 months ago
MNPR: And let alone try to explain that sudden (late-day) circa 240% soaring by @OCEA!!! And when one searches iHub's "ALL POSTS" about OCEA, one gets ambiguous posts about "Reddit was all over it", & "One guy threw $300,000 at it". BOY, that sure explains it all!!! (BONKERS STUFF, Bro!!)
👍️0
BurgerKing82 BurgerKing82 7 months ago
If there really is 15 million shares OS...That could explain the run...Granted it is a Day 2 on a Friday,the Run fizzled
👍️0
BurgerKing82 BurgerKing82 7 months ago
Wow it just crashed....idk what's next
👍️0
TimeFades TimeFades 7 months ago
Gamma squeeze
👍️0
TimeFades TimeFades 7 months ago
Still strong
👍️0
Invest-in-America Invest-in-America 7 months ago
MNPR: So am I, Dude!! NOTHING anymore makes any reasonable sense at all!!! (Their cheap FLUFF "news" of yesterday --- a mere Pre-Clinical Cancer stuff routine --- was patently UN-impressive at its core!! Yet today it soars!!)
👍️0
BurgerKing82 BurgerKing82 7 months ago
Off to a bad Start...surprised there isn't any posters,on this board...Some wild moves in either direction
👍️0
da_stock_analyst da_stock_analyst 7 months ago
#MNPR 🔥 gap fill to $2-$3 coming? Big upside! $MNPR
👍️0
BurgerKing82 BurgerKing82 7 months ago
How many shares OS?
👍️0
TimeFades TimeFades 7 months ago
A lot of dumping
👍️0
TimeFades TimeFades 7 months ago
Spring tight ready for 1.5
👍️0
TimeFades TimeFades 7 months ago
Yup keeps popping off trend line
👍️0
Invest-in-America Invest-in-America 7 months ago
MNPR: You yourself have posted this sentiment countless times, Boss!!! NONE of this 'Wall Street' stuff makes ANY (rational) sense at all!!!
👍️0
TheFinalCD TheFinalCD 7 months ago
yep and still goin
👍️0
Invest-in-America Invest-in-America 7 months ago
MNPR: The obvious WINNER of this day!!! (And all behind a mere PHASE-1 Cancer study routine!!! How the fluck can anyone call this stuff???!!!)
👍️0
TimeFades TimeFades 7 months ago
Level 2 just switched bullish
👍️0
Awl416 Awl416 7 months ago
Monopar Announces Promising Preclinical Data for its MNPR-101 Radiopharma Program Targeting Advanced Cancers
👍️0
Invest-in-America Invest-in-America 7 months ago
MNPR: WOW!! I hear-ya behind ALL of those notes, Boss!!! (And heck, I wouldn't mind being YOUR son --- his favorite 'WHEELS' is that red VET, no doubt??? Or, he's already FLIPPED a stock by himself, & bought his OWN Vet??? Naturally!!!)
👍️0
TheFinalCD TheFinalCD 7 months ago
OH IVE BEEN BURNT BAD BEFORE

I WAS JUST TELLING MY 17YR OLD SON WHO I AM TEACHING HIM ABOUT THE MARKET

I TOLD HIM I LOST -$80K ON A PHASE 1 THAT GAPPED AND TRAPPED ME AND SO MANY OTHERS

THAT WAS BRUTAL


AND I DID IT A FEW TIMES AFTER, THEN GAVE UP ON PHASE 1 STOCKS
👍️0
Fredric Fredric 7 months ago
💪🏿
👍️0
Invest-in-America Invest-in-America 7 months ago
MNPR: Well then, CONGRATS to ya, Dude!!! (& GOD BLESS!!!)
👍️0
Fredric Fredric 7 months ago
Yet n still I made money. You're expecting to much.

Just take your profits n let it be. Arguing about it isn't gonna change that.the price is going back up
N my free shares looking good

Learn to have fun. Not cry. We know companies send out pr to stop the bleeding n gain investors attention

That's why we invest.we don't marry. Everyone wants money.

Take it accordingly

Good day sir. I'm off to the next investment
👍️0
Invest-in-America Invest-in-America 7 months ago
MNPR: There was NOTHING to be made in the Pre-Market, either, Clown behind this scam!!! In case you didn't know that!!!
👍️0
Fredric Fredric 7 months ago
Took original plus extra holding a few for just in case.

That's how u trade
👍️0
Fredric Fredric 7 months ago
Riding free shares
👍️0
Fredric Fredric 7 months ago
Smh 🤦🏿‍♂️ HOMEBOY

You missed the point. Keep up.. Best bet is to trade with the big boys premarket in sell at open

Or buy after hours sell at premarket or open.

Flip in the case of last minute pr

Stop looking for a reason to argue

No one will listen to your rubbish

We don't need your explanation. Just say what you gotta say n leave it at that
👍️0
Invest-in-America Invest-in-America 7 months ago
MNPR: Myself, I am NOT "embarrassed", because I wasn't dumb enough to even THINK about buying this baloney sandwich (Pre-Colombian-Technology) "News". And certainly YOU --- Admiral TFCD --- weren't stupid enough either.
👍️0
Invest-in-America Invest-in-America 7 months ago
MNPR: And that "bet" is now OVER, Homeboy!! (Cheap --- merely Phase-1 "news" --- & still hyping old RADIATION gadgets!!! Stay AWAY from this kind of Pre-Colombian medical "technology"!!!)
👍️0
Fredric Fredric 7 months ago
Best bet
👍️0
Invest-in-America Invest-in-America 7 months ago
MNPR: This type of LAST MINUTE news is deliberately launched as such --- as if everyone doesn't yet know that. (HA-HAAAA!! Flip it really QUICK, if ya all grabbed some of this clever PR launch!!)
👍️0
Fredric Fredric 7 months ago
We will see
👍️0
Fredric Fredric 7 months ago
I hate when halts. Its gonna one of those days

Instituionals halting to take profit

It willhold for while think we see 1000% minimum

I was hoping for 50$ runner on strength n hype.but if they keep halting it we will see 10 -15$

👍️0
TheFinalCD TheFinalCD 7 months ago
LETS SEE IF THIS HOLDS OR ANOTHER ALL DAY FADER???
👍️0
Fredric Fredric 7 months ago
👀 very
👍️0
Fredric Fredric 7 months ago
Premarket is always where the big money buy and sell.
We must trade accordingly.

This is no different. Just gott get in where we fit in
👍️0
TheFinalCD TheFinalCD 7 months ago
ITS FLYING BUT BE CAREFUL iVE LOST SO MUCH $$$$ ON PHASE 1 PREMARKET PUMPS

IM EMBARRASSED



https://www.globenewswire.com/news-release/2024/02/20/2831765/0/en/Monopar-Receives-Clearance-to-Proceed-with-First-in-Human-Phase-1-Trial-of-Novel-Radiopharmaceutical-MNPR-101-Zr-in-Advanced-Cancers.html
👍️0
Awl416 Awl416 7 months ago
Wild
👍️0

Your Recent History

Delayed Upgrade Clock